TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Part A: Relapsed or refractory leukemia for which no standard therapies are anticipated to result in a durable remission~* Part B: AML who have had no more than two prior relapses or failed to achieve remission after at least one induction treatment.~* Patients with prior allogeneic transplants who remain clinically stable for ≥2 weeks or more off immunosuppressive therapy~Exclusion Criteria:~* Promyelocytic acute myelogenous leukemia~* Prior allogeneic transplant requiring immunosuppressive therapy or treating physician does not consider patient to be a candidate for allogeneic transplantation.~* Liver injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* undergoing ambulatory inguinal and/or abdominal surgery amenable to a Transversus Abdominis Plane nerve block (unilateral or bilateral).~* expected postoperative pain to be at least moderate in severity the day following surgery~* age 18 years or older~* desires a regional anesthetic for postoperative analgesia~* is able to understand the possible perineural infusion-related complications, study protocol, and catheter/pump care~* has a caretaker through the first night after surgery~* has an ASA Physical Status Classification of 1-3~Exclusion Criteria:~* any contraindication for a continuous Transversus Abdominis Plane nerve block~* any physical, mental or medical conditions which, in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery.~* current chronic opioid or tramadol use~* history of alcohol or opioid abuse~* know allergy or other contraindication to the study medication~* pregnancy~* known hepatic or renal insufficiency/disease~* peripheral neuropathy of the surgical site~* morbid obesity~* inability to communicate with the investigators and hospital staff~* incarceration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single injection with Saline infused TAP catheter (Type: PLACEBO_COMPARATOR): Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given normal saline in infusion pump, attached to catheter.
- Single injection with Ropivicaine infused TAP catheter (Type: ACTIVE_COMPARATOR): Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given 0.2% ropivicaine in infusion pump, attached to catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A CFit Study - Acute Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ≥ 12 years of age~* CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride \> 60 mmol·L-1 \> 100 mg sweat) and, where possible, diagnostic genotyping~* No contraindications to performing exhaustive exercise~* Can understand and cooperate with the study protocol~* No increase in symptoms or weight loss in the preceding 2 weeks~Exclusion Criteria:~* Any non-pulmonary conditions that may impair exercise ability, such as musculoskeletal disorders (arthritis, joint or muscle disease) and cardiovascular disease (congenital heart disease or cardiomyopathy).~* Unstable co-morbid asthma (daily pulmonary function variability of \> 20%)~* Is pregnant during the initial screening process~* Unable to understand or cooperate with the study protocol due to learning difficulties or otherwise~* Not of a suitable age for testing~Exclusion during testing:~* Onset of acute infection~* Becomes and/or is tested to be pregnant following enrolment to the study~* Experiences significant hypoxaemia during visit 2 of the CFit_BL protocol (IRAS ID: 225310) which requires supplemental O₂. Under these circumstances, participants will be invited to continue their participation under the CFit_BL trial (IRAS ID: 225310)~* Unable to understand or cooperate with study protocol~* The individual does not wish to participate further

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moderate vs. High-intensity exercise (randomised) (Type: EXPERIMENTAL): Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (MIE completed first)
- High-intensity vs. Moderate intensity exercise (randomised) (Type: EXPERIMENTAL): Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (HIIE completed first)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Toffee Full Face and Toffee Nasal Mask Evaluation in Obesity Hypoventilation Syndrome (NZ)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18+~* Diagnosed with OHS by a practicing physician~* Existing full face mask user or a nasal mask user~* Prescribed PAP therapy (Bi-Level or CPAP)~Exclusion Criteria:~* Inability to give informed consent~* Pregnant or think they may be pregnant~* Anatomical or physiological conditions making PAP therapy inappropriate~* Patients requiring supplemental oxygen with their PAP device~* Patients who are in a coma or decreased level of consciousness~* Existing Toffee full face and Toffee nasal mask users~* No arterial PCO2 value from their medical records

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Full face/Nasal masks (Type: EXPERIMENTAL): Toffee Full face/Toffee nasal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MOTIVATE: Moving to Improve Outcomes for Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 50 and older~* English- speaking~* Working telephone~* Capable of participating in home-based activity~* Chronic low back pain with intensity of 4 or higher on 10 point scale~* Self-reported low back pain (+/-radiation) in the past 3 months that interferes with daily activities on most days~* Depression, PHQ-9\>10 stable (per chart review, no psychotic or suicidal ideation; confirmed over telephone)~Exclusion Criteria:~* Aged 49 or less~* No telephone~* Not English speaking~* Unwilling to be randomized to either study arm~* Self-reported, uncorrected hearing or visual disturbance precluding ability to participate in telephone sessions or read pedometer screen~* Cognitive impairment, assessed by Memory Impairment Screen~* Lumbar surgery within the last year~* Self-reported dependence on wheelchair, bed-bound, or severe balance impairment (unable to participate in physical activity intervention)~* Illness requiring hospitalization within the last 3 months (e.g., fall, gout attacks, stroke, heart attack, heart failure, or surgery for blocked arteries)~* Suicidal ideation or prior psychotic episodes requiring hospitalization within the last year

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Waitlist Control Group (Type: NO_INTERVENTION): The waitlist control group will continue with management of chronic back pain and depression per usual care. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the same intervention once the active intervention group has completed the active sessions and assessments.
- Behavioral Intervention Group (Type: EXPERIMENTAL): For participants assigned to the intervention arm, trained health coaches will deliver the intervention via telephone. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Endarteritis~* Hypovascularity~* Diarrhea~* Cramping~* Obstruction~* Stricture~* Pain~* Hemorrhage~* Wall Changes~* Ulceration~* Hypocellularity~* Mucosal thickening~* Vomiting~* Tenesmus~* Constipation~* Perforation~* Fistula~* Obstipation~* Tissue hypoxia~Exclusion Criteria:~* Pregnancy~* Reactive airway disease~* Radiographic evidence of pulmonary blebs or bullae~* Untreated pneumothorax~* Previously documented ejection fraction less than 35%~* History of seizures except childhood febrile seizures~* Cardiovascular instability~* Mechanical ventilator support with the exception of those patients who are immediately (1-5 days) post-operative~* Unable to follow simple commands~* Not orientated to person, place, time~* Participating as a subject in any other medical or biomedical research project; if previously involved as a subject, sufficient time must have elapsed to permit wash out of any investigational agent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Hyperbaric Oxygen Therapy
- B (Type: SHAM_COMPARATOR): Normal Air

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High Dose Vitamin D vs Standard Dose Vitamin D Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All participants must be female and at least 21 years of age~* Signed informed consent~* Patients must have had histologically confirmed stage I-III breast carcinoma that is positive for Estrogen Receptor (ER) and/or Progesterone Receptor (PR).~* Post-menopausal~* Beginning adjuvant aromatase inhibitor therapy, with no previous use within the last 6 weeks~* Bisphosphonates are allowed at the treating investigator¡¦s discretion~* Performance status (WHO/ECOG scale) 0-2.~Exclusion Criteria:~* History of kidney stones~* Hypercalcemia at baseline, defined as any corrected calcium greater than the laboratory's normal parameters~* History of either symptomatic hypercalcemia or hyperparathyroidism, at the treating investigator's discretion~* Baseline Vitamin D level greater than 50 ng/mL~* Inability or unwillingness to comply with, or follow study procedures.~* Currently taking Phenytoin or phenobarbital -7 Currently taking cholestyramine or orlistat~* Malabsorption syndrome, such as Crohn's disease~Prohibited Therapies: Patients may not take additional Calcium and Vitamin D aside from the study medications. Patients who are on cholestyramine or orlistat will not be allowed on the trial. Also, patients who are taking phenytoin or phenobarbital are not allowed on the trial either because of interaction between Vitamin D and anti-epileptic medications.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High Dose Vitamin D ARM (Type: EXPERIMENTAL): 50,000 IU Vitamin D supplement
- 800 IU Vitamin D Supplement (Type: ACTIVE_COMPARATOR): 800 IU Vitamin D Supplement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: (understood to include only abstemious women)~1. . Pregnant women expected to deliver between 37 and 41 weeks gestation (controls), and their babies~2. . Pregnant women expected to deliver between 37 and 41 weeks gestation who have class A1 diabetes mellitus, and their babies~3. . Pregnant women expected to deliver between 37 and 41 weeks gestation who have class A2 diabetes mellitus, and their babies~4. . Pregnant women expected to deliver between 37 and 41 weeks gestation who were diagnosed with diabetes mellitus prior to their pregnancy, and their babies.~Exclusion Criteria:~1. . Mothers who self-reported any alcohol or any illicit drug use during their pregnancy (and their babies)~2. . Mothers who had a positive drug screen at any point during their pregnancy (and their babies)~3. . Babies whose mothers suffered a placental abruption during their pregnancy.~4. . Babies whose mothers had inadequate prenatal care (defined as \<3 prenatal clinic visits prior to admission for delivery)~5. . Non-English-speaking mothers~6. . Babies who pass meconium in utero.~7. . Babies born with multiple congenital anomalies or abdominal wall defects.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: None): Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).
- A1 IDM (Type: None): Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).
- A2 IDM (Type: None): Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).
- PGDM - IDM (Type: None): Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Camera Based System to Monitor Patient Movement During Radiation Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with tumors of the brain, head and neck, thorax, upper abdomen, posterior spine/sacrum and extremities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin for Central Sensitization in TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing native joint unilateral TKA due to Grade 3-4 primary osteoarthritis~* Patients with score of at least 40 on Central Sensitization Inventory~* Patients who will complete PT within the U of Iowa Health Care system~* Patients who have been nonsmokers for \> 2 years~* Patients between the ages of 50 and 85~Exclusion Criteria:~* Patients already taking pregabalin or had an adverse effect with pregabalin in the past~* Patients indicated for joint revision surgery~* Patients taking at least 30 morphine milligram equivalents per day for the past 1 month~* Patients with an estimate GFR \< 30 ml/min~* Patients who do not have an understanding of English~* Patients who are pregnant or women of child-bearing years~* Patients who are prisoners~* Patients who score \< 40 on the CSI~* Patients who answer Yes to any questions on the Columbia Suicide Severity Rating Scale or express suicidal ideation

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Participants will receive standard peri-operative pain management
- Study (Pregabalin) (Type: EXPERIMENTAL): Participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days. Then Stop.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed non-small cell lung cancer with a clinical stage of IIIA~* Candidate for chemoradiation and surgical resection~* Measurable disease~* Life expectancy \> 6 months~* Normal organ and marrow function~Exclusion Criteria:~* Pregnant or breast-feeding~* Prior therapy for lung cancer with chemotherapy~* Prior chest radiation~* Compromised pulmonary function~* Severe neurovascular disease~* History of high cardiac risk including unstable angina~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin or etoposide~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive hear failure, unstable angina pectoris, clinically significant or serious cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* History of a different malignancy unless disease-free for at least 3 years and at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, non muscle-invasive bladder cancer, basal cell or squamous cell carcinoma of the skin~* Subjects with HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiation, Chemotherapy and Surgery (Type: EXPERIMENTAL): Proton beam radiation, plus chemotherapy with cisplatin and etoposide, followed by surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Venous Vascularization and Inflammation on Contrast-enhanced Ultrasound (CEUS) in Patients With Thrombosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years~* acute, idiopathic or provoked, unilateral proximal DVT (involving the popliteal vein or further proximal veins)~* SVT (more than 5cm in length on compression ultrasonography) of the lower- extremity~* Age and sex matched controls will be recruited from volunteers after exclusion of DVT or SVT, and without history of thrombosis and pulmonary embolism~Exclusion Criteria:~* History of previous DVT or SVT of the lower-extremity~* History of pulmonary embolism~* Bilateral DVT or SVT~* DVT associated with intravenous drug abuse, surgery of the lower-extremity in the previous 10 days, or sclerotherapy in the previous 30 days~* Follow-up is not considered feasible~* Heart failure (HYHA III or IV)~* Acute coronary syndrome (\<7d)~* Severe pulmonal-arterial hypertension (pulmonal arterial pressure \>90mmHg)~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Thrombosis (Type: None): Patients with acute, idiopathic or provoked, unilateral proximal DVT (involving the popliteal vein or further proximal veins) and SVT of the lower-extremity detected with duplex ultrasound.~Age and sex matched controls (volunteers)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues